Prediction: This Quantum Computing Stock Is Going to Plummet Over the Next 12 Months

Rigetti generated just $5.1 million of Q2 2026 revenue despite 185% year-over-year growth, versus $30.2 million in operating costs and a $52.6 million net loss. Its $5 billion market capitalization implies a 374x trailing P/S ratio, or 61x the Nasdaq-100's 6.1x multiple; even on the $44.1 million 2027 consensus revenue forecast, forward P/S remains 114x. While the company held $541 million of cash, commercialization may still be years away, raising the risk of future debt or equity financing and shareholder dilution; the article argues shares could fall below $10, potentially to $5, if revenue expectations are missed.

Analysis

RGTI is priced as a scarce-asset proxy for quantum rather than as a business with a near-term underwriting framework. That makes the key variable not quarterly revenue growth but the cadence of technical milestones relative to cash burn: any slippage in fidelity, system uptime, or customer conversion can trigger multiple compression because there is little recurring revenue base to cushion a reset. Its vertically integrated fabrication model is strategically valuable only if it produces a demonstrable iteration-speed advantage; otherwise it embeds fixed-cost absorption risk versus better-capitalized platform competitors such as IBM and Alphabet.

The likely 1-3 month setup is asymmetric on disappointing guidance or an equity-registration/shelf filing, but outright shorting carries meaningful meme/retail-flow and low-float squeeze risk. A more durable 6-18 month pressure point is dilution: investors are currently underwriting eventual fault-tolerant economics while the company must fund several technology cycles before commercial demand is likely to support the cost structure. The relevant comparison is not Nasdaq multiples but the probability-weighted value of a pre-commercial R&D asset, where incremental capital raises can transfer a disproportionate share of future upside from current holders to new investors.

Consensus bearish commentary may still understate a countervailing risk: a credible technical benchmark, strategic government award, or hyperscaler distribution agreement could re-rate the entire listed quantum basket before revenue validates it. The cleaner expression is therefore relative value, not a large naked short. Watch next earnings for cash-use trajectory, backlog quality, and evidence that paid workloads—not research access or pilot activity—are scaling; sustained improvement in those indicators would falsify the short thesis.

Key Decisions for Investors

• Initiate a modest 3-6 month RGTI bearish-risk-reversal or put spread only after confirming option liquidity and implied volatility; target a 2:1 payoff profile, with premium at risk capped because technical-news squeezes can be violent.
• Prefer a pair trade: short RGTI versus long IBM in dollar-neutral size over 6-12 months. IBM offers quantum optionality funded by an operating business, while RGTI remains most exposed to financing and execution risk; exit if RGTI secures a material commercial partnership with disclosed multiyear economics.
• Set an event-driven short alert on any capital-markets filing or guidance miss, rather than chasing weakness after bearish media coverage. Increase exposure only if quarterly operating cash use fails to improve while paid customer revenue/backlog does not accelerate.
• Avoid treating NVDA as a direct quantum read-through. The more plausible second-order effect is that stronger classical AI economics raise the hurdle rate for quantum workloads; monitor enterprise compute budgets and quantum-specific procurement disclosures before positioning in semiconductor suppliers.